




















- significant fibrosis in patients with chronic hepatitis C," *Hepatology*, vol. 45, no. 2, pp. 297–306, 2007.
- [29] A. S. F. Lok, M. G. Ghany, Z. D. Goodman et al., "Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort," *Hepatology*, vol. 42, no. 2, pp. 282–292, 2005.
- [30] G. Sebastiani, L. Castera, P. Halfon et al., "The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases," *Alimentary Pharmacology & Therapeutics*, vol. 34, no. 10, pp. 1202–1216, 2011.
- [31] C.-T. Wai, C. L. Cheng, A. Wee et al., "Non-invasive models for predicting histology in patients with chronic hepatitis B," *Liver International*, vol. 26, no. 6, pp. 666–672, 2006.
- [32] W. Jin, Z. Lin, Y. Xin, X. Jiang, Q. Dong, and S. Xuan, "Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis B-related fibrosis: a leading meta-analysis," *BMC Gastroenterology*, vol. 12, article 14, 2012.
- [33] H. Enomoto, Y. Sakai, N. Aizawa et al., "Association of amino acid imbalance with the severity of liver fibrosis and esophageal varice," *Annals of Hepatology*, vol. 12, no. 3, pp. 471–478, 2013.
- [34] M. Eslam, J. Ampuero, M. Jover et al., "Predicting portal hypertension and variceal bleeding using non-invasive measurements of metabolic variables," *Annals of Hepatology*, vol. 12, no. 4, pp. 588–598, 2013.



Hindawi
Submit your manuscripts at
<http://www.hindawi.com>



Entecavir and interferon- α sequential therapy in Japanese patients with hepatitis B e antigen-positive chronic hepatitis B

Masaru Enomoto · Shuhei Nishiguchi · Akihiro Tamori · Sawako Kobayashi · Hiroki Sakaguchi · Susumu Shiomi · Soo Ryang Kim · Hirayuki Enomoto · Masaki Saito · Hiroyasu Imanishi · Norifumi Kawada

Received: 8 April 2012 / Accepted: 5 July 2012 / Published online: 2 August 2012
© Springer 2012

Abstract

Background The outcomes of sequential therapy with lamivudine followed by interferon have been unsatisfactory in Japanese patients with hepatitis B envelope antigen (HBeAg)-positive chronic hepatitis B. However, the efficacy of sequential therapy with entecavir and interferon remains unclear.

Methods Twenty-four HBeAg-positive patients (23 men and 1 woman; mean age 39 ± 7 years) received entecavir 0.5 mg alone for 36–52 weeks, followed by entecavir plus interferon- α for 4 weeks, and lastly by interferon- α alone for 20 weeks. Twenty-three patients had genotype C infection, and one had genotype A infection.

Results No entecavir-resistant mutant variants emerged in any patient. Hepatitis flare occurred in three patients during

interferon- α treatment after the withdrawal of entecavir, but none had hepatic decompensation. Serum hepatitis B surface antigen levels did not change during or after therapy. Serum hepatitis B core-related antigen levels were significantly decreased at the start ($P < 0.0001$) and at the end of interferon- α treatment ($P < 0.0001$), but returned to baseline levels after treatment. Twenty-four weeks after the completion of the sequential therapy, a sustained biochemical, virological, and serological response was achieved in 5 (21 %) patients. The proportion of patients in whom HBeAg was lost during entecavir treatment was significantly higher among those with a sustained response than among those with no response ($P = 0.015$).

Conclusions The rate of response to sequential therapy with entecavir and interferon- α in Japanese patients with HBeAg-positive chronic hepatitis B was not higher than the rate in previous studies of lamivudine followed by interferon.

Keywords Chronic hepatitis B · Genotypes · Interferon- α · Entecavir · Sequential therapy

For the B-SHOT Study Group.

Other members of the B-SHOT Study Group are listed in the Appendix.

M. Enomoto · A. Tamori · S. Kobayashi · H. Sakaguchi · N. Kawada (✉)
Department of Hepatology, Osaka City University Graduate School of Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan
e-mail: kawadanori@med.osaka-cu.ac.jp

S. Nishiguchi · H. Enomoto · M. Saito · H. Imanishi
Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan

S. Shiomi
Department of Nuclear Medicine, Osaka City University Graduate School of Medicine, Osaka, Japan

S. R. Kim
Department of Gastroenterology, Kobe Asahi Hospital, Hyogo, Japan

Introduction

Infection with hepatitis B virus (HBV) remains an important public health problem and a leading cause of liver-related morbidity worldwide [1, 2]. The natural course of chronic HBV infection acquired perinatally or during infancy consists of three distinct phases: ‘immune tolerant’, ‘immune reactive’, and ‘inactive carrier’. During the immune-reactive phase, rises in alanine aminotransferase (ALT) are attributable to the host’s immune response to HBV, and the occurrence of hepatitis will eventually be followed by spontaneous seroconversion from hepatitis B

envelope antigen (HBeAg) to anti-HBe. HBeAg seroconversion usually results in clinical remission and a life-long inactive state; however, patients with persistently detectable HBeAg and high HBV DNA levels who have recurrent hepatitis flares are at increased risk of developing cirrhosis and hepatocellular carcinoma [3, 4].

Currently available antiviral treatment for chronic hepatitis B includes nucleos(t)ide analogues such as lamivudine, adefovir, entecavir, and tenofovir, and the immunomodulator interferon [5–7]. The direct, potent antiviral effects of nucleos(t)ide analogues induce biochemical and virological responses in most patients, but viral relapse and exacerbations of hepatitis commonly occur after discontinuation of treatment. Long-term use of nucleos(t)ide analogues is associated with the emergence of drug-resistant variants possessing mutations in the HBV polymerase gene. In contrast, interferon-induced remission of chronic hepatitis B is durable, but is achieved in only a minority of patients. In randomized controlled trials, concomitant treatment with lamivudine and interferon- α has offered little clinical benefit, in terms of the rates of sustained therapeutic response, as compared with interferon- α alone [8, 9].

Serfaty et al. [10] reported that sequential therapy with lamivudine followed by interferon- α was effective in patients with chronic hepatitis B. In their pilot study in France, sustained virological and biochemical response was achieved in 8 (57 %) of the 14 patients who received lamivudine 100 mg alone for 20 weeks, followed by interferon- α 5 MU 3 times/week plus lamivudine for 4 weeks, and lastly by interferon- α alone for 24 weeks [10]. Some other groups have studied similar protocols for sequential therapy, but results have been conflicting [11–17]. The inconsistent results may have been caused, at least in part, by differences in the included HBV genotypes among studies, because HBV genotypes have specific geographic distributions and can affect the response to interferon [18, 19]. In our previous study [14], the rate of response to sequential therapy with lamivudine and interferon in 24 Japanese HBeAg-positive patients with chronic HBV genotype C infection was 29 %, considerably lower than the rate reported by Serfaty et al. [10].

Randomized controlled trials have shown that entecavir has higher antiviral activity against HBV than lamivudine [20, 21]. Among licensed nucleos(t)ide analogues, entecavir is used as a first-line treatment of choice for chronic hepatitis B, similar to tenofovir disoproxil fumarate [22]. Use of a potent nucleoside analogue before the initiation of interferon may improve the outcomes of sequential therapy.

In this study, we evaluated the efficacy of sequential therapy with entecavir and interferon- α in Japanese patients with HBeAg-positive chronic hepatitis B. In addition to the

monitoring of serum HBeAg and HBV DNA levels, serum hepatitis B surface antigen (HBsAg) and hepatitis B core-related antigen (HBcrAg) [23, 24] levels were monitored during and after sequential therapy. The clinical characteristics of patients who had a sustained response to the sequential therapy were compared with those of patients who had no response.

Patients and methods

Patients

The subjects were 24 Japanese patients with HBeAg-positive chronic hepatitis B (23 men and 1 woman; mean age 39 ± 7 years) who had received sequential therapy with entecavir alone and then entecavir plus interferon- α followed by interferon- α alone between September 2006 and August 2011. The inclusion criteria were as follows: (1) persistent or fluctuating elevations of serum ALT levels for at least 6 months before the start of therapy; (2) presence of HBsAg in serum; (3) presence of HBeAg and absence of anti-HBe; (4) presence of HBV DNA $>10^5$ copies/mL (equivalent to 20,000 IU/mL); (5) no use of corticosteroids or immunomodulatory drugs, including interferon, within 1 year before the start of therapy; (6) no use of nucleos(t)ide analogues, such as lamivudine, within 1 year before the start of therapy; (7) absence of resistance to nucleos(t)ide analogues; (8) absence of antibodies to hepatitis C virus and other likely causes of chronic liver disease; and (9) no clinical signs of decompensated cirrhosis or hepatocellular carcinoma. The study procedures were in accordance with the Helsinki Declaration of 1975 (1983 revision) and were approved by the ethics committee of each participating center. Written informed consent was obtained from each patient. This study was registered in the UMIN Clinical Trials Registry (registration ID number, UMIN00000808).

Treatment

Patients were treated with entecavir alone for 36–52 weeks, followed immediately by both entecavir and interferon- α for 4 weeks, and lastly by interferon- α alone for 20 weeks. Entecavir (Baraclude; Bristol-Myers, Tokyo, Japan) was given orally at a dose of 0.5 mg once daily. Natural interferon- α (Otsuka Pharmaceutical, Tokyo, Japan) was given by intramuscular injection, at a dose of 5 MU, three times a week for 24 weeks (a protocol commonly used in Japan during the study period). All patients were followed up for at least 24 weeks after the completion of treatment, and responses to therapy were assessed as follows: *biochemical response* was defined as a decrease in

serum ALT levels to within the normal range; *virological response* was defined as a decrease in serum HBV DNA to $<10^4$ copies/mL; and a *serological response* was defined as loss of serum HBeAg. A sustained response was defined as fulfillment of the criteria for combined biochemical, virological, and serological responses 24 weeks after the end of therapy.

Assays

The following variables were determined for all enrolled patients: complete blood counts; serum ALT level; HBsAg, HBeAg, anti-HBe, HBcrAg, and HBV DNA levels; HBV genotypes; proportion of mutants in the precore and basal core promoter regions of HBV DNA; and drug-resistant mutations in the HBV polymerase gene.

Complete blood counts and serum ALT (upper limit of normal, 30 IU/L) were determined by standard procedures. HBsAg was measured with a chemiluminescent micro-particle immunoassay (Architect HBsAg QT; Abbott Japan, Tokyo, Japan) as described elsewhere [25]. HBeAg and anti-HBe were detected with chemiluminescence enzyme immunoassays. HBcrAg was also detected with a chemiluminescence enzyme immunoassay (Fuji-Rebio, Tokyo, Japan) [23]. HBV DNA was measured with a real-time polymerase chain reaction (PCR) assay (COBAS TaqMan HBV Test v2.0; Roche Diagnostics, Tokyo, Japan) [26]. Genotypes of HBV were identified by enzyme-linked immunosorbent assay with monoclonal antibodies to type-specific epitopes in the preS2-region (Institute of Immunology, Tokyo, Japan) [27]. Mutations at nucleotide (*nt*) 1896 in the precore region and at *nt* 1762 and *nt* 1764 in the basal core promoter region of HBV DNA were found by means of an enzyme-linked minisequence assay (Genome Science Laboratory, Tokyo, Japan). Drug-resistant mutations (at codons 180, 181, 184, 202, 204, 236, and 250 of the HBV reverse transcriptase domain) were detected by PCR-Invader technology (BML, Tokyo, Japan) [28].

Histopathology

When informed consent had been obtained, a liver biopsy was performed before the patient started therapy. Histopathological findings were assessed by grading inflammatory activity and staging fibrosis according to the METAVIR scoring system [29]. An experienced pathologist blinded to the clinical data performed these evaluations.

Statistical analysis

Statistical analysis was performed with SAS, version 9.2 for Windows (SAS Institute, Cary, NC, USA).

Distributions of continuous variables were analyzed with the non-parametric Mann–Whitney *U*-test. Differences in proportions were tested by Fisher’s exact test. The significance of changes in values between two time points was evaluated by the Wilcoxon signed-rank test. A two-tailed *P* value of less than 0.05 was considered to indicate statistical significance.

Results

Rate of response to therapy

Although common interferon- α -related side effects included pyrexia, fatigue, headache, and myalgia, the therapy was well tolerated, and all patients completed the treatment according to the protocol. The proportions of patients with biochemical, virological, and serological responses during and after sequential therapy with entecavir and interferon- α are shown in Fig. 1. Drug-resistant mutant variants did not emerge in any patient during entecavir treatment. At the start of interferon- α treatment (about 1 year after the start of the entecavir treatment), most patients had normal ALT levels and serum HBV DNA levels of $<10^4$ copies/mL




Fig. 1 Rate of biochemical, virological, and serological responses during and after sequential therapy with entecavir and interferon- α . Combined sustained biochemical, virological, and serological response was achieved in 5 (21 %) of the 24 enrolled patients 24 weeks after completion of the sequential therapy. ALT Alanine aminotransferase, HBeAg hepatitis B envelope antigen, HBV hepatitis B virus, IFN interferon

(88 and 100 %, respectively). However, loss of HBeAg was achieved in a minority of patients (29 %) during the entecavir treatment.

In most patients without HBeAg loss at the end of the entecavir treatment, serum ALT and HBV DNA levels increased even during the interferon- α treatment. Hepatitis flare (defined as a rise in ALT equivalent to 10 times higher than the upper limit of normal and more than twice the baseline value) occurred in 3 patients after the withdrawal of entecavir. Although peak ALT levels in these patients were 693, 721, and 876 IU/L, respectively, none had jaundice or hepatic decompensation. At the end of the interferon- α treatment, the percentages of patients with normal ALT, HBV DNA $<10^4$ copies/mL, and loss of HBeAg were 75, 71, and 33 %, respectively.

Lastly, 24 weeks after the completion of the sequential therapy, a sustained biochemical, virological, and serological response was achieved in 5 (21 %) of the 24 patients. No patient had loss of serum HBsAg in response to the sequential therapy.

Changes in HBsAg and HBcrAg during and after sequential therapy

Changes in serum HBsAg and HBcrAg levels during and after the sequential therapy with entecavir and interferon- α are shown in Fig. 2. The serum HBsAg level did not change significantly during or after the therapy (Fig. 2a).

The serum HBcrAg levels were significantly decreased at the start ($P < 0.0001$) and at the end of interferon- α treatment ($P < 0.0001$), but returned to baseline levels after completion of the sequential treatment (Fig. 2b). The serum HBsAg level did not differ significantly between patients with a sustained response and those with no response (Fig. 2c). In contrast, the serum HBcrAg level was significantly lower in patients with a sustained response than in those with no response at the end of the interferon- α therapy ($P = 0.013$) and 24 weeks post-treatment ($P = 0.031$) (Fig. 2d).

Characteristics of patients at the start of entecavir treatment

The baseline demographic, biochemical, virological, and histological characteristics of patients at the start of entecavir treatment, classified according to the response to sequential therapy, are listed in Table 1. The mean age of patients with a sustained response was more than 10 years less than that of the patients with no response, but this difference did not reach statistical significance ($P = 0.102$). There were no significant differences between the two groups with respect to sex ratio, proportion of patients with a history of interferon treatment, ALT level, HBV DNA level, ratios of HBV genotypes, ratios of precore or basal core promoter mutants, or histopathological findings in the liver.

Fig. 2 Changes in serum levels of hepatitis B surface antigen (HBsAg) and hepatitis B core-related antigen (HBcrAg) during and after sequential therapy with entecavir and interferon- α . Serum HBsAg levels did not change during or after therapy (a). As compared with the baseline value, the serum HBcrAg level was significantly decreased at the start ($P < 0.0001$) and at the end of interferon- α treatment ($P < 0.0001$) (asterisks) (b). When sustained responders were compared with non-responders, there was no significant difference in the serum HBsAg level (c). In contrast, the serum HBcrAg level was significantly lower in sustained responders than in non-responders at the end of interferon- α therapy ($P = 0.013$) and 24 weeks post-treatment ($P = 0.031$) (asterisks) (d)




Table 1 Baseline characteristics of patients at the start of entecavir treatment

Characteristics	Sustained responders (n = 5)	Non-responders (n = 19)	P values
Age (years)	29 ± 6	41 ± 5	0.10
Male sex (%)	5 (100 %)	18 (95 %)	0.99
History of interferon treatment (%)	3 (60 %)	12 (63 %)	0.99
ALT (IU/L)	85 (65, 322)	210 (79, 531)	0.37
HBV DNA (log ₁₀ copies/mL)	7.7 ± 0.4	7.8 ± 0.8	0.31
Genotype (A/B/C/D)	0/0/5/0	1/0/18/0	0.99
Precore (wild/mixed/mutant)	0/4/1	9/9/1	0.12
Basal core promoter (wild/mixed/mutant)	1/0/4	5/8/6	0.070
Grade of inflammation (mild/moderate/severe)	2/3/0	9/7/2	0.60
Stage of fibrosis (mild/moderate/severe/cirrhosis)	2/2/0/1	10/5/3/0	0.19

Values are means ± SDs for normally distributed variables, and medians (with the interquartile range) for non-normally distributed variables
 ALT alanine aminotransferase, HBV hepatitis B virus

Table 2 Characteristics of patients at the start of interferon-α treatment

Characteristics	Sustained responders (n = 5)	Non-responders (n = 19)	P values
ALT (IU/L)	24 (23, 35)	20 (15, 32)	0.27
ALT normal (%)	5 (100 %)	16 (84 %)	0.99
HBV DNA (log ₁₀ copies/mL)	2.1 ± 0.3	2.3 ± 0.4	0.18
HBV DNA negative (%)	3 (60 %)	6 (32 %)	0.33
HBeAg loss (%)	4 (80 %)	3 (16 %)	0.015

Values are means ± SDs for normally distributed variables, and medians (with the interquartile range) for non-normally distributed variables
 HBeAg hepatitis B envelope antigen

Characteristics of patients at the start of interferon-α treatment

The characteristics of the patients at the start of interferon-α treatment, classified according to the response to sequential therapy, are shown in Table 2. The responders and non-responders did not differ significantly with respect to ALT level or HBV DNA level at the start of interferon-α treatment. The proportion of patients in whom HBeAg was lost during entecavir treatment was significantly higher among those with a sustained response than among those with no response (*P* = 0.015). In another comparison, a sustained response was achieved in 4 (57 %) of the 7 patients with loss of HBeAg during entecavir treatment, as compared with 1 (5.9 %) of the 17 patients without loss of HBeAg during treatment; this difference was also statistically significant (*P* = 0.015).

Case presentation

A 24-year-old man with no response to previous treatment with interferon-α was referred to us (Fig. 3). His ALT level




Fig. 3 Changes in platelet count, ALT, HBeAg, anti-HBe, and HBV DNA in a 24-year-old man with sustained response to sequential therapy with entecavir and interferon-α. In the upper panel, the changes in ALT levels (filled circles) and platelet counts (open circles) are shown. In the lower panel, the changes in HBV DNA (filled circles) and anti-HBe (open circles) titers are shown. During 1 year of entecavir treatment, the platelet count rose from 87,000 to 199,000/mm³. After the patient was switched to interferon-α, his anti-HBe antibody titer increased. At the most recent hospital visit, the patient's ALT level was normal, HBeAg was negative, and HBV DNA was negative; the patient has remained drug-free since the completion of treatment

was 617 IU/L, HBV DNA level was 7.6 log₁₀ copies/mL, and HBV genotype was C. A precore stop codon mutation at nt 1896 and basal core promoter mutations at nt 1762 and nt 1764 were detected. A liver biopsy showed moderate inflammation and cirrhosis. Although the patient was young, interferon-α was not indicated because of a low platelet count and concern about exacerbation of hepatitis. However, during 1 year of entecavir treatment, his ALT level became normal, and his platelet count rose from 87,000 to 199,000/mm³. After switching to interferon-α, his HBV DNA rose transiently, but his anti-HBe antibody titer increased. At the most recent hospital visit (up to 35 weeks after the completion of treatment), his ALT level was normal and HBeAg and HBV DNA were negative; the

patient has remained drug-free since the completion of treatment.

Discussion

Several groups have evaluated protocols for sequential therapy with lamivudine and interferon- α , and their protocols were similar to that originally described by Serfaty et al. [10]. Manesis et al. [11], from Greece, where HBV genotype D is predominant, found that in HBeAg-negative patients, the rate of sustained biochemical and virological response was 22 %, which did not differ from that obtained in an age/sex-matched historical control group treated with interferon- α alone. In another report from Greece [12], sequential combination therapy significantly prevented the emergence of resistance to lamivudine, but the rate of sustained virological response was only 17 % among HBeAg-negative patients. A group from China, where genotype B or C is predominant, reported very similar results [13]. To date, only the study by Moucari et al. [17] has used adefovir dipivoxil instead of lamivudine. Sustained virological response was achieved in 50 % of their subjects, although only 20 HBeAg-negative patients were included.

In Japan and other countries in East Asia, genotype C is the most prevalent type of HBV [18, 19], and most patients with chronic hepatitis B acquire the virus perinatally or in early childhood [7]. The rates of response to interferon are thus lower than those reported in Europe and the United States. In our previous study [14], using a sequential therapy protocol similar to that described by Serfaty et al. [10], we found that the rate of sustained response was only 29 % among 24 HBeAg-positive patients. The patients with a sustained response were significantly younger and had a significantly lower HBV DNA level at the start of interferon than did those with no response. The rate of HBeAg loss during lamivudine treatment was slightly but not significantly higher among sustained responders than among non-responders. Minami and Okanou [15] also found that patients who lost HBeAg during lamivudine treatment were more likely to have a sustained response to sequential therapy. Okuse et al. [16] reported that sequential therapy was effective for patients with acute exacerbations of chronic hepatitis B, particularly those in whom HBeAg had become negative during lamivudine treatment.

One objective of sequential therapy is to lower the viral load by the use of a nucleos(t)ide analogue, thereby restoring sensitivity to interferon treatment. In clinical studies, a low HBV DNA level is predictive of a favorable response to interferon- α [30, 31]. In basic studies, a high viral load is associated with T-cell hyporesponsiveness [32], and treatment with nucleos(t)ide analogues restores

cellular immune response in chronic HBV infection [33]. Although lamivudine had been administered for about half a year before the start of interferon administration in previous studies (including ours) [10–16], we administered entecavir, a more potent antiviral agent, for about 1 year in the present study. Treatment with entecavir was given for a longer period because it has been reported in previous studies that patients in whom HBeAg and HBV DNA levels were lowered by lamivudine were more likely to have a sustained response and because few entecavir-resistant variants emerge within the first few years [34]. However, the use of entecavir for a longer duration did not raise the rate of off-treatment sustained response to sequential therapy in the present study, although the rate of on-treatment biochemical and virological responses was higher with entecavir than that obtained with lamivudine in our previous study [14].

Another objective of sequential therapy is to prevent the relapse of hepatitis after discontinuation of the nucleos(t)ide analogue through the use of interferon- α . Nucleos(t)ide analogues rapidly decrease serum HBV DNA levels by suppressing the reverse transcription of pregenomic HBV RNA, but viral relapse commonly occurs after the cessation of treatment. This high risk of viral relapse may be attributed to the persistence of HBV replicative intermediate covalently closed circular DNA (cccDNA) in the liver even during nucleos(t)ide treatment. The measurement of HBV antigens in serum is thus clinically important as a surrogate marker of intrahepatic cccDNA. In particular, a decline in serum levels of HBsAg is strongly associated with response to interferon- α [35]. The HBcrAg assay measures serum levels of all antigens transcribed from the precore/core gene, including hepatitis B core and e antigens, by using monoclonal antibodies that recognize common epitopes of the denatured antigens [23, 24]. Matsumoto et al. [36] recently proposed a model for predicting relapse of hepatitis after discontinuation of nucleos(t)ide analogue administration, in which cut-off values were set at 1.9–2.9 log₁₀ IU/mL of HBsAg and 3.0–4.0 log₁₀ U/mL of HBcrAg at the withdrawal of treatment. In our study, only one patient had a decrease in HBsAg to between 1.9 and 2.9 log₁₀ IU/mL and another one had a decrease in HBcrAg to between 3.0 and 4.0 log₁₀ U/mL at the withdrawal of entecavir (data not shown), probably because of an insufficient duration of entecavir treatment in our protocol. The finding that at least 21 % of our patients with insufficient HBsAg and HBcrAg decline during entecavir treatment achieved a sustained response to sequential therapy suggests that switching to interferon- α contributes to the safe termination of nucleos(t)ide analogue treatment in some patients.

The major advantages of interferon- α include a finite course of treatment, the opportunity to obtain an off-treatment durable response to therapy, and absence of drug resistance. The advantages of nucleos(t)ide analogues include good tolerance and potent antiviral activity associated with high rates of on-treatment response to therapy. Guidelines proposed by the Japanese Study Group of the Standardization of Treatment of Viral Hepatitis basically recommend interferon- α as the first-line treatment for patients with chronic hepatitis B who are younger than 35 years, to attain a ‘drug-free state’; and entecavir for patients who are 35 years or older, to persistently suppress HBV DNA [37]. Consistent with the findings of previous studies [14–16], our results show that sequential therapy is best indicated for patients who have lost HBeAg during nucleoside analogue treatment, because such patients have a higher probability of a sustained response. As shown in Fig. 3, patients who are young but have exacerbation of hepatitis, cirrhosis, or both, were also good candidates for sequential therapy, because interferon- α is generally not recommended for such patients because of concern about hepatic decompensation, and the preceding use of a nucleos(t)ide analogue can reduce such risk.

Our study had several limitations. First, it was not a randomized controlled trial. The reported rate of HBeAg seroconversion obtained by 6-month interferon- α monotherapy among Japanese patients was about 20 % [38], which is similar to the rate obtained by the sequential therapy used in our study (21 %). As compared with our previous study of lamivudine [14], the rate of sustained response in our present study of entecavir did not differ significantly (21 % in the entecavir group vs. 29 % in the lamivudine group). Although the patients were not randomly assigned to treatment, the baseline characteristics of the subjects did not differ between those in our previous study of lamivudine and those in the present study of entecavir with respect to mean age, sex ratio, ALT level, HBV DNA level, ratios of HBV genotypes, ratios of precore or basal core promoter mutants, or histopathological findings (data not shown). Thus, we cannot conclude that sequential therapy with entecavir and interferon- α is more effective than interferon- α monotherapy or sequential therapy with lamivudine and interferon- α . Second, we gave patients non-pegylated interferon- α for 6 months, because pegylated interferon- α had not been approved for the treatment of chronic hepatitis B by the Japanese medical insurance system during the study period. Further studies are thus needed to evaluate the efficacy of sequential therapy with entecavir and pegylated interferon- α .

To our knowledge, this is the first study to report on the response to sequential therapy with entecavir and

interferon- α in patients with chronic hepatitis B. In summary, an off-treatment sustained response to sequential therapy with entecavir and interferon- α was achieved in 21 % of HBeAg-positive patients with chronic hepatitis B in Japan, where genotype C is predominant. This rate of response was not higher than that in our previous study using lamivudine [14]. Patients who had loss of HBeAg during entecavir treatment were more likely to have a sustained response to sequential therapy.

Acknowledgments The authors are grateful to Ms. Sanae Deguchi, Ms. Rie Yasuda, and Ms. Ami Saito for their technical assistance. This work was supported in part by a grant from the Ministry of Health, Labour and Welfare, Japan.

Conflict of interest Dr. Shuhei Nishiguchi has received research grants from Bristol-Myers K.K. and Otsuka Pharmaceutical Co., Ltd. Dr. Norifumi Kawada has received research grants from Bristol-Myers K.K. and Otsuka Pharmaceutical Co., Ltd.

Appendix

In addition to the authors, the B-SHOT Study Group includes the following persons: Kohshun Kim, Motoharu Tanaka (Higashi Sumiyoshi Morimoto Hospital, Osaka, Japan); Hideji Nakamura, Hiroko Iijima, Soji Shimomura, Noritoshi Koh, Yoshinori Iwata, Yoshiyuki Sakai, Tomoyuki Takashima (Hyogo College of Medicine, Nishinomiya, Japan); Tetsuo Yamamoto (Kita-Osaka Police Hospital, Osaka); Hirokazu Kadoya (Izumiotu Municipal Hospital, Osaka); Chika Kawamura (Ohno Memorial Hospital, Osaka); Kiyohide Kioka, Yasuko Kawasaki (Osaka City General Hospital, Osaka); Osamu Kurai, Hiroko Oka (Osaka City Juso Hospital, Osaka); Daiki Habu, Hiroyasu Morikawa, Shuji Iwai, Hideki Fujii (Osaka City University Medical School, Osaka); Katsuhiko Fukuda (PL Hospital, Osaka); Machiko Shintani (Sumiyoshi Municipal Hospital, Osaka); and Hisato Jomura (Wakakokai Hospital, Osaka).

References

1. Dienstag JL. Hepatitis B virus infection. *N Engl J Med*. 2008;359:1486–500.
2. Liaw YF, Chu CM. Hepatitis B virus infection. *Lancet*. 2009;373:582–92.
3. Iloeje U, Yang H, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. *Gastroenterology*. 2006;130:678–86.
4. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. *JAMA*. 2006;295:65–73.
5. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. *Hepatology*. 2009;50:661–2.

6. European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. *J Hepatol*. 2009;50:227–42.
7. Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. *Hepatol Int*. 2008;2:263–83.
8. Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. *Lancet*. 2005;365:123–9.
9. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. *N Engl J Med*. 2005;352:2682–95.
10. Serfaty L, Thabut D, Zoulim F, Andreani T, Chazouillères O, Carbonell N, et al. Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: results of a pilot study. *Hepatology*. 2001;34:573–7.
11. Manesis EK, Papatheodoridis GV, Hadziyannis SJ. A partially overlapping treatment course with lamivudine and interferon in hepatitis B e antigen-negative chronic hepatitis B. *Aliment Pharmacol Ther*. 2006;23:99–106.
12. Vassiliadis T, Tziomalos K, Patsiaoura K, Zagris T, Giouleme O, Souferis K, et al. Lamivudine/pegylated interferon alfa-2b sequential combination therapy compared with lamivudine monotherapy in HBeAg-negative chronic hepatitis B. *J Gastroenterol Hepatol*. 2007;22:1582–8.
13. Shi M, Wang RS, Zhang H, Zhu YF, Han B, Zhang Y, et al. Sequential treatment with lamivudine and interferon-alpha monotherapies in hepatitis B e antigen-negative Chinese patients and its suppression of lamivudine-resistant mutations. *J Antimicrob Chemother*. 2006;58:1031–5.
14. Enomoto M, Tamori A, Kohmoto MT, Hayashi T, Morikawa H, Jomura H, et al. Lamivudine and IFN-beta sequential therapy in HBe antigen-positive patients with chronic hepatitis B virus genotype C infection. *J Interferon Cytokine Res*. 2007;27:201–7.
15. Minami M, Okanoue T. Management of HBV infection in Japan. *Hepatol Res* 2007; 37(s1):S79–82.
16. Okuse C, Yotsuyanagi H, Yamada N, Okamoto M, Ikeda H, Kobayashi M, et al. Effect of nucleoside analog-interferon sequential therapy on patients with acute exacerbation of chronic hepatitis B. *Hepatol Res*. 2010;40:461–9.
17. Mouchari R, Boyer N, Ripault MP, Castelnaud C, Mackiewicz V, Dauvergne A, et al. Sequential therapy with adefovir dipivoxil and pegylated Interferon Alfa-2a for HBeAg-negative patients. *J Viral Hepat*. 2011;18:580–6.
18. Orito E, Ichida T, Sakugawa H, Sata M, Horiike N, Hino K, et al. Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan. *Hepatology*. 2001; 34:590–4.
19. Enomoto M, Tamori A, Nishiguchi S. Hepatitis B virus genotypes and response to antiviral therapy. *Clin Lab*. 2006;52:43–7.
20. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. *N Engl J Med*. 2006;354:1001–10.
21. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. *N Engl J Med*. 2006;354:1011–20.
22. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. *N Engl J Med*. 2008;359:2442–55.
23. Kimura T, Rokuhara A, Sakamoto Y, Yagi S, Tanaka E, Kiyosawa K, et al. Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load. *J Clin Microbiol*. 2002;40:439–45.
24. Rokuhara A, Tanaka E, Matsumoto A, Kimura T, Yamaura T, Orii K, et al. Clinical evaluation of a new enzyme immunoassay for hepatitis B virus core-related antigen; a marker distinct from viral DNA for monitoring lamivudine treatment. *J Viral Hepat*. 2003;10:324–30.
25. Kohmoto M, Enomoto M, Tamori A, Habu D, Takeda T, Kawada N, et al. Quantitative detection of hepatitis B surface antigen by chemiluminescent microparticle immunoassay during lamivudine treatment of chronic hepatitis B virus carriers. *J Med Virol*. 2005;75:235–9.
26. Hochberger S, Althof D, Gallegos de Schrott R, Nachbaur N, Röck H, Leying H. Fully automated quantitation of hepatitis B virus (HBV) DNA in human plasma by the COBAS AmpliPrep/COBAS TaqMan system. *J Clin Virol*. 2006;35:373–80.
27. Usuda S, Okamoto H, Iwanari H, Baba K, Tsuda F, Miyakawa Y, et al. Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in the preS2-region product. *J Virol Methods*. 1999;80:97–112.
28. Tadokoro K, Suzuki F, Kobayashi M, Yamaguchi T, Nagano M, Egashira T, et al. Rapid detection of drug-resistant mutations in hepatitis B virus by the PCR-Invader assay. *J Virol Methods*. 2011;171:67–73.
29. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. *Hepatology*. 1996;24:289–93.
30. Perrillo RP, Schiff ER, Davis GL, Bodenheimer HC Jr, Lindsay K, Payne J, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. *N Engl J Med*. 1990;323:295–301.
31. Lok AS, Wu PC, Lai CL, Lau JY, Leung EK, Wong LS, et al. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. *Gastroenterology*. 1992;102:2091–7.
32. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. *Annu Rev Immunol*. 1995;13:29–60.
33. Boni C, Bertolotti A, Penna A, Cavalli A, Pilli M, Urbani S, et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. *J Clin Invest*. 1998;102:968–75.
34. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. *Hepatology*. 2009;49:1503–14.
35. Sonneveld MJ, Rijckborst V, Boucher CA, Hansen BE, Janssen HL. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. *Hepatology*. 2010;52: 1251–7.
36. Matsumoto A, Tanaka E, Suzuki Y, Kobayashi M, Tanaka Y, Shinkai N, et al. Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B. *Hepatol Res*. 2012;42:139–49.
37. Kumada H, Okanoue T, Onji M, Moriawaki H, Izumi N, Tanaka E, et al. Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis B virus infection for the fiscal year 2008 in Japan. *Hepatol Res*. 2010;40:1–7.
38. Suzuki F, Arase Y, Akuta N, Tsubota A, Suzuki Y, Sezaki H, et al. Efficacy of 6-month interferon therapy in chronic hepatitis B virus infection in Japan. *J Gastroenterol*. 2004;39:969–74.

Combination therapy with a nucleos(t)ide analogue and interferon for chronic hepatitis B: simultaneous or sequential

Masaru Enomoto · Akihiro Tamori ·
Shuhei Nishiguchi · Norifumi Kawada

Received: 2 October 2012 / Accepted: 11 December 2012 / Published online: 22 January 2013
© Springer Japan 2013

Abstract Currently available antiviral treatment for chronic hepatitis B virus infection can be divided into two classes of therapeutic agents: nucleos(t)ide analogues (NAs) and interferon (IFN). The major advantages of NAs are good tolerance and potent antiviral activity associated with high rates of on-treatment response to therapy; the advantages of IFN include a finite course of treatment, absence of drug resistance, and an opportunity to obtain a post-treatment durable response to therapy. The use of these two antiviral agents with different mechanisms of action in combination is theoretically an attractive approach for treatment. Here, we have reviewed previous reports of either simultaneous or sequential combination therapy with NA and IFN for chronic hepatitis B patients. In previous studies comparing the lamivudine/IFN combination and lamivudine monotherapy in a finite course, combination therapy was associated with higher rates of sustained post-treatment response and lower rates of drug resistance than lamivudine monotherapy. However, NAs such as lamivudine are generally administered indefinitely because of high rates of post-treatment relapse. In addition, concern for drug resistance has decreased significantly with newer, high-potency NAs even when administered alone. In previous studies comparing the lamivudine/IFN combination and IFN monotherapy, the combination therapy showed greater on-treatment viral suppression, but no

difference was observed in the post-treatment sustained response. Thus, whether combination therapy confers an additional benefit compared to monotherapy for treating chronic hepatitis B remains unclear. The efficacy of IFN in combination with a more potent NA, such as entecavir or tenofovir, remains to be comprehensively evaluated.

Keywords Chronic hepatitis B · Lamivudine · Adefovir · Entecavir · Interferon · Nucleos(t)ide analogue

Abbreviations

ALT	Alanine aminotransferase
CccDNA	Covalently closed circular DNA
HBcrAg	Hepatitis B core-related antigen
HBeAg	Hepatitis B e antigen
HBsAg	Hepatitis B surface antigen
HBV	Hepatitis B virus
IFN	Interferon
NA	Nucleos(t)ide analogue

Introduction

More than 350 million people worldwide are infected with hepatitis B virus (HBV) which is a leading cause of liver-related morbidity that accounts for 1 million deaths annually [1, 2]. Currently available antiviral treatment for chronic hepatitis B can be divided into two classes of therapeutic agents: nucleos(t)ide analogues (NAs) and interferon (IFN). Nucleosides include lamivudine [3, 4], telbivudine [5], and entecavir [6, 7]; nucleotides include adefovir [8, 9] and tenofovir [10]. The direct, potent antiviral effects of NAs induce an on-treatment response in

M. Enomoto (✉) · A. Tamori · N. Kawada
Department of Hepatology,
Osaka City University Graduate School of Medicine, 1-4-3
Asahimachi, Abeno-ku, Osaka 545-8585, Japan
e-mail: enomoto-m@med.osaka-cu.ac.jp

S. Nishiguchi
Department of Internal Medicine,
Hyogo College of Medicine, Nishinomiya, Hyogo, Japan

most patients, but post-treatment relapse commonly occurs after treatment discontinuation. Long-term use of NAs triggers the emergence of drug-resistant variants possessing mutations in the hepatitis B virus (HBV) polymerase gene. Among the NAs currently available, entecavir or tenofovir is recommended as the first-line treatment because of the low rate of drug resistance. In contrast, IFN has both antiviral and immunomodulatory actions [11, 12]. The major advantages of IFN include a finite course of treatment, absence of drug resistance, and an opportunity to obtain a post-treatment durable response to therapy; however, a response to IFN is achieved in only a minority of patients with chronic hepatitis B.

In this article, we have reviewed previous reports on combination therapy with NA and IFN for chronic hepatitis B. Regimens of combination therapy can be classified into two main groups: (1) simultaneous therapy with the drugs in the combination and (2) sequential combination therapy in which treatment with one drug follows that of the previously administered one. To compare the results of previous trials, we noted that age/sex of the included subjects, HBV genotypes, and mode of viral transmission varies among the different studies. These differences may affect the results and their interpretations as older age, male sex, HBV genotypes C and D (vs. A and B), and vertical transmission are associated with a poor response to IFN therapy [13–15]. In particular, HBV genotypes have specific geographic distributions, with genotype A being prevalent in Northwest Europe, North America, and Central Africa, genotypes B and C being common in Southeast Asia, China, Japan, and Oceania, and genotype D being prevalent in Southern Europe, the Middle East, and India, although it has a nearly worldwide distribution.

Theoretical background

Nucleos(t)ide analogues directly inhibit viral replication by targeting at least one of the three replication steps: priming of HBV DNA polymerase, reverse transcription of negative-strand HBV DNA from pregenomic RNA, and synthesis of positive-strand HBV DNA. IFN also possesses antiviral activity but does not act directly on the virus or replication complex. Instead, it acts by inducing IFN-stimulated genes to establish a non-virus-specific antiviral state within the cell. In addition to their role as antivirals, IFNs are important immunomodulators that interact with the adaptive and innate immune responses. Combining NA and IFN, with their different mechanisms of action, in a therapeutic regimen is theoretically an attractive approach for treating chronic hepatitis B.

The action of NAs has little or no effect on the decrease in the intrahepatic HBV replicative intermediate,

covalently closed circular DNA (cccDNA). In the experimental woodchuck hepatitis virus system, cccDNA persisted even when viral production was strongly reduced by NA treatment [16, 17]. To reduce the level of intrahepatic cccDNA, the immunomodulatory activity of IFN, which presumably induces cytotoxic T cell activity for immune clearance of infected cells, may be required. However, a high HBV DNA load is associated with an inefficient T cell response to HBV-related antigens, such as hepatitis B surface antigen (HBsAg) [18]. Several studies have shown that a decreased viral load induced by NA treatment can result in the subsequent restoration of CD4 followed by CD8 cellular immune response against HBV [19, 20]. The rationale for combination therapy is based on the concept that suppression of viral replication by NA can decrease viral protein synthesis on the surface of hepatocytes, which may restore the immune response and optimize the immunomodulatory effects of IFN for clearing infected cells.

Simultaneous combination with NA and IFN

Table 1 shows a summary of previous studies examining simultaneous combination therapy with NA and IFN for chronic hepatitis B. The first trial was reported by Mutimer et al. [21] in the UK. Since this study was designed to assess the safety and tolerability of combination treatment, the duration of treatment was only 16 weeks, and few patients showed sustained seroconversion from hepatitis B e antigen (HBeAg) to anti-HBe (antibody to HBe) by this short-term therapy with lamivudine and IFN- α . Barbaro et al. [22] reported the results of a randomized trial conducted in Italy where the 24-week combination with lamivudine and IFN- α increased the rate of sustained HBeAg seroconversion compared to the 52-week lamivudine monotherapy (33 vs. 15 %; $P = 0.014$). Tatulli et al. [23] in Italy found that the 52-week combination with lamivudine and IFN- α resulted in a sustained loss of serum HBV DNA, based on the results of a solution hybridization assay, and normalization of alanine aminotransferase (ALT) in only 14 % of HBeAg-negative patients, but drug-resistant mutation variants did not emerge in any patients. However, from these previous studies, it is still unclear whether combination therapy with lamivudine and IFN confers an additional benefit compared to IFN monotherapy.

Three randomized controlled trials (2 in HBeAg-positive patients [24, 25] and 1 in HBeAg-negative patients [26]) did not show that 1-year combination therapy with lamivudine and pegylated IFN- α was superior to monotherapy with pegylated IFN- α in terms of the rate of sustained response. The results of these globally conducted

Table 1 Simultaneous combination therapy with nucleos(t)ide analogues and interferon

Reference (first author)	HBeAg	n (genotype)	Age (years)	Male (%)	Regimens	Biochemical response (%)	Virologic response (%)
Mutimer [21]	+	20 (N.D.)	39 ± 11 ^a	95	LAM + IFN for 12–16 weeks	0	5
Barbaro [22]	+	76 (N.D.)	42 (33–50) ^b	84	LAM + IFN for 24 weeks	37	33
Tatulli [23]	–	29 (N.D.)	44 (27–64) ^b	90	LAM + IFN for 52 weeks	14	14
Janssen [24]	+	130 (A43/B11/C18/D52)	34 ± 12 ^a	75	LAM + PEG for 52 weeks	35	35
Lau [25]	+	271 (A18/B82/C156/D11)	32 ± 10 ^a	77	LAM + PEG for 48 weeks	39	28
Marcellin [26]	–	179 (N.D.)	41 ± 11 ^a	82	LAM + PEG for 48 weeks	60	44
Wursthorn [29]	±	26 (A8/B0/C1/D14)	34 (19–55) ^b	77	ADV + PEG for 48 weeks	N.D.	N.D.
Takkenberg [30]	±	40 (A20/B2/C2/D9)	40 ± 10 ^a	88	ADV + PEG for 48 weeks	N.D.	50

HBeAg hepatitis B e antigen, LAM lamivudine, ADV adefovir dipivoxil, IFN interferon, PEG pegylated interferon, N.D. not described

^a Mean (± standard deviation, SD)

^b Median (range)

trials, which included many patients with various HBV genotypes, appear to be reliable. All studies found that the combination therapy had greater on-treatment viral suppression and higher rates of sustained post-treatment response than therapy with lamivudine alone, but no difference was observed in the sustained post-treatment virologic response compared to that with pegylated IFN- α alone. Janssen et al. [24], for example, found that more patients in the patient group receiving the 52-week pegylated IFN- α + lamivudine combination than in the group receiving the 52-week pegylated IFN- α monotherapy showed a response, as assessed by serum HBeAg loss at the end of treatment (44 vs. 29 %; $P = 0.01$). However, this difference was not sustained; 35 % of the combination-therapy group and 36 % of the monotherapy group showed a sustained HBeAg loss at the end of follow-up ($P = 0.91$). The trial also showed that pegylated IFN- α therapy improves liver histology, particularly in responders to therapy, but that the addition of lamivudine to therapy with pegylated IFN- α did not further improve histological outcome [27] and that genotypes C and D are associated with a lower rate of response to IFN than genotypes A and B.

To date, few studies have examined the combination of IFN and other NAs that are more potent than lamivudine. The telbivudine + IFN combination is prohibited because of the high risk of severe polyneuropathy [28]. Interestingly, Wursthorn et al. [29] from Germany found that 48-week combination therapy with adefovir dipivoxil and pegylated IFN- α led to marked decreases in cccDNA in the liver, which has been correlated with reduced HBsAg in

serum. However, the rate of the post-treatment sustained response was not reported in this study. Another group from the Netherlands [30] showed that intrahepatic cccDNA levels at the end of 48-week treatment with adefovir dipivoxil and pegylated IFN- α were predictive of a sustained response defined as HBV DNA <2,000 IU/mL and normal ALT. The efficacy of combining IFN and other NAs, such as entecavir or tenofovir, remains to be elucidated.

Sequential combination starting with IFN followed by NA

Table 2 shows a summary of previous reports concerning sequential combination therapy starting with IFN followed by NAs for chronic hepatitis B. Hasan et al. reported that the rate of sustained HBeAg seroconversion was only 6.2 % in patients in Kuwait receiving IFN- α alone for 4 weeks, followed by the IFN- α + lamivudine combination for 12 weeks, and lastly by lamivudine alone for 36 weeks; this rate was similar to that observed in patients receiving lamivudine alone for 48 weeks [31].

In contrast, a randomized trial by Chan et al. in China [32] showed that the rate of sustained virologic response, defined as HBeAg seroconversion and a HBV DNA level of <500,000 copies/mL, was 36 % in patients receiving pegylated IFN- α alone for 8 weeks, followed by the pegylated IFN- α + lamivudine combination for 24 weeks, and lastly by lamivudine alone for 28 weeks; this rate was

Table 2 Sequential combination therapy starting with IFN followed by nucleos(t)ide analogues

Reference (first author)	HBeAg	n (genotype)	Age (years)	Male (%)	Regimens	Biochemical response (%)	Virologic response (%)
Hasan [31]	+	32 (N.D.)	32 (17–63) ^b	88	IFN for 4 weeks, IFN + LAM for 12 weeks, and then LAM for 36 weeks	9.3	6.2
Chan [32]	+	50 (A0/B18/C35/D0)	32 (19–57) ^b	62	PEG for 8 weeks, PEG + LAM for 24 weeks, and then LAM for 28 weeks	50	36

^a Mean (range)^b Median (range)

significantly higher than that observed in patients receiving lamivudine alone for 52 weeks (14 %; $P = 0.011$). At the end of the treatment period, 21 % of patients in the sequential combination treatment group developed a lamivudine-resistant mutant, compared to 40 % of patients in the lamivudine monotherapy group. Follow-up of this study demonstrated that sequential combination with pegylated IFN- α followed by lamivudine maintained a higher long-term virologic response than lamivudine monotherapy for up to 3 years [33]. However, this study did not include a study arm of pegylated IFN- α alone.

Sequential combination starting with NA followed by IFN

Table 3 shows a summary of previous studies which examined sequential combination therapy starting with NAs followed by IFN for chronic hepatitis B. In a pilot study [34] by Serfaty et al. in France, sustained responses, defined as serum HBV DNA clearance based on the results of a branched DNA assay and ALT normalization, were achieved in 57 % of patients who received lamivudine alone for 20 weeks followed by the lamivudine + IFN- α combination for 4 weeks, and lastly by IFN- α alone for 24 weeks.

Some groups have studied similar protocols for sequential therapy, but the results have been conflicting. Consistent with the results reported by Serfaty et al. [34], Sarin et al. [35] in India reported that the addition of 4-week lamivudine before starting 24-week pegylated IFN- α therapy resulted in a significantly higher rate of sustained HBeAg clearance (39 %) than that with 24-week pegylated IFN- α monotherapy (14 %; $P = 0.05$). In contrast, Manesis et al. [36] found that in HBeAg-negative patients in Greece, where genotype D is predominant, the rate of sustained response to sequential therapy, defined as HBV DNA of $\leq 30,000$ copies/mL and normal ALT, was only 22 %, which did not differ from that obtained in age/sex-matched historical controls treated with IFN- α alone for 12 months (14 %; $P = 0.36$). In another report in Greece [37], sequential therapy did not raise the rate of sustained

virologic response, defined as HBV DNA levels of < 400 copies/mL, in HBeAg-negative patients compared to lamivudine monotherapy for a median duration of 25 months (33 vs. 17 %; $P = 0.40$), although no patients in the sequential therapy group showed emerging resistance to lamivudine. A group in China, where genotype B or C is predominant, reported very similar results [38].

In Japan and other East Asian countries, genotype C is the most prevalent HBV type [39, 40], and most patients with chronic hepatitis B acquire the virus perinatally [13]. Thus, response rates to IFN-based therapy in these countries are lower than those reported in Europe and the USA. In our previous study [41] using sequential therapy with lamivudine alone for 16–32 weeks, followed by the lamivudine + IFN combination for 4 weeks and lastly by IFN alone for 20 weeks, the rate of sustained loss of HBeAg was only 29 %. The rate of HBeAg loss during lamivudine treatment was higher among sustained responders than that among non-responders. In a multicenter trial, Minami et al. [42] found that patients who lost HBeAg during lamivudine treatment were more likely to show a sustained response to sequential therapy. Okuse et al. [43] reported that sequential therapy was effective for patients with acute exacerbations of chronic hepatitis B, particularly those in whom HBeAg had become negative during lamivudine treatment.

To date, a small study by Moucari et al. [44] from France has been the only one to evaluate the efficacy of sequential therapy with adefovir dipivoxil followed by IFN- α . Sustained virologic response, defined as serum HBV DNA of $< 10,000$ copies/mL, was achieved in 50 % of patients, but only 20 HBeAg-negative patients were included in this study.

We recently reported the outcomes of sequential therapy with entecavir followed by IFN- α [45]. Among the 24 patients receiving entecavir alone for 36–52 weeks, followed by the entecavir + IFN- α combination for 4 weeks, and lastly by IFN- α alone for 20 weeks, the rate of sustained response, defined by HBeAg loss, HBV DNA of $< 10,000$ copies/mL, and normal ALT, was 21 %; this was not higher than the rate found in our previous study using lamivudine [41]. In the study carried out in China, Chen

Table 3 Sequential combination therapy starting with a nucleos(t)ide analogue followed by IFN

Reference (first author)	HBeAg	n (genotype)	Age (years)	Male (%)	Regimens	Biochemical response (%)	Virologic response (%)
Serfaty [34]	±	14 (A6/B0/C1/D4)	40 (30–57) ^a	100	LAM for 20 weeks, followed by LAM + IFN for 4 weeks, and then IFN for 24 weeks	57	57
Sarin [35]	+	36 (N.D.)	33 ± 11 ^b	93	LAM for 4 weeks, followed by PEG for 24 weeks	36	39
Manesis [36]	–	36 (N.D.)	55 (46–66) ^a	69	LAM for 6 months, followed by LAM + IFN for 6 months, and then IFN for 6 months	39	22
Vassiliadis [37]	–	18 (N.D.)	42 (19–63) ^a	83	LAM for 3 months, followed by LAM + PEG for 3 months, and then by PEG for 9 months	72	33
Shi [38]	–	64 (N.D.)	35 (21–56) ^a	60	LAM for 20 weeks, followed by LAM + IFN for 4 weeks, and then IFN for 24 weeks	53	14
Enomoto [41]	+	24 (C)	37 ± 11 ^b	88	LAM for 16–32 weeks, followed by LAM + IFN for 4 weeks, and then IFN for 20 weeks	46	29
Minami [42]	±	37 (N.D.)	N.D.	N.D.	LAM for 20 weeks, followed by LAM + IFN for 4 weeks, and then IFN for 20 weeks	46	35
Okuse [43]	±	12 (C)	32 ± 8 ^b	83	LAM for 20 weeks, followed by LAM + IFN for 4 weeks, and then IFN for 20 weeks	N.D.	58
Moucari [44]	–	20 (A5/B3/C1/D9)	44 (41–52) ^a	85	ADV for 20 weeks, followed by ADV + PEG for 4 weeks, and then PEG for 44 weeks	50	50
Enomoto [45]	+	24 (A1/B0/C23/D0)	39 ± 7 ^b	96	ETV for 36–52 weeks, followed by ETV + IFN for 4 weeks, and then IFN for 20 weeks	29	21
Chen [46]	±	32 (A0/B23/C9/D0)	35 ± 5 ^b	72	ETV for 12–26 days, followed by ETV + PEG for 2 weeks, and then PEG for 22–46 weeks	61	74

^a Median (range)^b Mean (± SD)

ETV Entecavir

et al. [46] included only patients with acute exacerbation (ALT >10-fold the upper limit of normal) who were treated with entecavir alone for 12–26 days before the ALT had declined to five- to ten-fold the upper limit of normal, followed by the entecavir + pegylated IFN- α combination for 2 weeks, and then by pegylated IFN- α alone for 22–46 weeks. Sustained virologic response, defined as HBV DNA of <10,000 copies/mL, was obtained in 69 % of HBeAg-positive and in 80 % of HBeAg-negative patients with acute exacerbation of chronic hepatitis B.

One objective of sequential therapy starting with NA is to lower the viral load before IFN therapy is initiated, thereby restoring treatment sensitivity as low HBV DNA levels are associated with a favorable response to IFN. Another objective of sequential therapy is to prevent the relapse of hepatitis following the discontinuation of NA therapy through the use of IFN. The high risk of viral relapse after treatment may be attributed to the persistence of cccDNA in the liver, which is correlated with HBV antigen levels in the serum. Using HBsAg and hepatitis B core-related antigen (HBcrAg) levels, Matsumoto et al. [47] proposed a model for predicting relapse after the discontinuation of NA therapy. In our study of sequential therapy using entecavir [45], few patients showed a decrease in HBsAg or HBcrAg to the level meeting the criteria

of safe discontinuation of NA. Taken together with the fact that at least 21 % of our patients achieved a sustained response, we suggest that the switch to IFN- α contributes to the safe termination of NA therapy in some patients [48].

Combination with NA and IFN in the guidelines

Combination therapy with NA and IFN is not recommended in the guidelines proposed by the Asian-Pacific Association for the Study of the Liver (updated in 2008) [13] and the American Association for the Study of Liver Diseases (updated in 2009) [14] because there has been no large clinical trial to confirm the benefits of combination therapy over monotherapy in inducing a higher rate of sustained response. The most recently updated guidelines proposed by the European Association for the Study of the Liver (updated in July 2012) [15] also does not recommend combination therapy of IFN with lamivudine or telbivudine. However, the limited information currently available on the efficacy and safety of combining IFN with other NAs has raised an unresolved issue of assessing the safety and efficacy of combining IFN with a more potent NA, such as entecavir or tenofovir.

Guidelines proposed by the Japanese Study Group of the Standardization of Treatment of Viral Hepatitis [49] basically recommend IFN as the first-line treatment for chronic hepatitis B patients aged <35 years to attain a “drug-free state” and entecavir for patients aged ≥ 35 years to persistently suppress HBV DNA (as tenofovir disoproxil fumarate has not been licensed in Japan to date). In patients aged <35 years and harboring HBV DNA in titers of ≥ 7 log copies/mL, sequential treatment with entecavir followed by IFN is recommended as the first-line therapy if HBeAg is negative and as the second-line therapy (next to IFN monotherapy) if HBeAg is positive. In patients aged ≥ 35 years and harboring HBV DNA of ≥ 7 log copies/mL, sequential treatment is recommended as the second-line therapy (next to entecavir) if the HBeAg is positive.

Conclusions

It remains unclear whether combination therapy is superior to monotherapy for treating chronic hepatitis B. Consequently, controlled trials comparing combination and monotherapy are necessary. In previous studies comparing the lamivudine + IFN combination and lamivudine monotherapy in a finite course, combination therapy was associated with higher rates of sustained post-treatment response and lower rates of drug resistance than lamivudine monotherapy. However, NAs are generally administered indefinitely due to high rates of post-treatment relapse. Additionally, even when NAs are administered alone, concern for drug resistance has significantly decreased (≤ 1.2 % in 3–5 years [50, 51]) with the development of newer high-potency NAs, such as entecavir and tenofovir. In previous studies comparing the lamivudine + IFN combination and IFN monotherapy, combination therapy showed greater on-treatment viral suppression, but no difference in the post-treatment sustained response was observed when compared to therapy with IFN alone. The efficacy of combining IFN with a more potent NA remains to be evaluated. Further studies are needed to determine whether switching to IFN contributes to the safe discontinuation of therapy, particularly in patients with decreased HBsAg and/or HBcAg levels during long-term NA treatment [52].

Conflict of interest Dr. S. Nishiguchi has received research grants from Bristol-Myers K.K., MSD K.K., and Chugai Pharmaceutical Co., Ltd. Dr. N. Kawada has received grants from Bristol-Myers K.K., MSD K.K., and Chugai Pharmaceutical Co., Ltd.

References

- Dienstag JL. Hepatitis B virus infection. *N Engl J Med.* 2008;359:1486–500.
- Liaw YF, Chu CM. Hepatitis B virus infection. *Lancet.* 2009;373:582–92.
- Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. *N Engl J Med.* 1998;339:61–8.
- Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. *N Engl J Med.* 1999;341:1256–63.
- Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. *N Engl J Med.* 2007;357:2576–88.
- Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. *N Engl J Med.* 2006;354:1001–10.
- Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. *N Engl J Med.* 2006;354:1011–20.
- Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. *N Engl J Med.* 2003;348:808–16.
- Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. *N Engl J Med.* 2005;352:2673–81.
- Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. *N Engl J Med.* 2008;359:2442–55.
- Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. *Ann Intern Med.* 1993;119:312–23.
- Yang YF, Zhao W, Xia HM, Zhong YD, Huang P, Wen J. Long-term efficacy of interferon alpha therapy on hepatitis B viral replication in patients with chronic hepatitis B: a meta-analysis. *Antiviral Res.* 2010;85:361–5.
- Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. *Hepatol Int.* 2008;2:263–83.
- Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. *Hepatology.* 2009;50:661–2.
- European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. *J Hepatol.* 2012;57:167–85.
- Moraleda G, Saputelli J, Aldrich CE, Averett D, Condreay L, Mason WS. Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus. *J Virol.* 1997;71:9392–9.
- Dandri M, Burda MR, Will H, Petersen J. Increased hepatocyte turnover and inhibition of woodchuck hepatitis B virus replication by adefovir in vitro do not lead to reduction of the closed circular DNA. *Hepatology.* 2000;32:139–46.
- Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. *Annu Rev Immunol.* 1995;13:29–60.
- Boni C, Bertolotti A, Penna A, Cavalli A, Pilli M, Urbani S, et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. *J Clin Invest.* 1998;102:968–75.
- Boni C, Penna A, Ogg GS, Bertolotti A, Pilli M, Cavallo C, et al. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. *Hepatology.* 2001;33:963–71.
- Mutimer D, Naoumov N, Honkoop P, Marinos G, Ahmed M, de Man R, et al. Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: results of a pilot study. *J Hepatol.* 1998;28:923–9.

22. Barbaro G, Zechini F, Pellicelli AM, Francavilla R, Scotto G, Bacca D, et al. Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial. *J Hepatol*. 2001;35:406–11.
23. Tatulli I, Francavilla R, Rizzo GL, Vinciguerra V, Ierardi E, Amoruso A, et al. Lamivudine and alpha-interferon in combination long term for precore mutant chronic hepatitis B. *J Hepatol*. 2001;35:805–10.
24. Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, et al. Pegylated interferon alpha-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. *Lancet*. 2005;365:123–9.
25. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. *N Engl J Med*. 2005;352:2682–95.
26. Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. *N Engl J Med*. 2004;351:1206–17.
27. van Zonneveld M, Zondervan PE, Cakaloglu Y, Simon C, Akarca US, So TM, et al. Peg-interferon improves liver histology in patients with HBeAg-positive chronic hepatitis B: no additional benefit of combination with lamivudine. *Liver Int*. 2006;26:399–405.
28. Marcellin P, Avila C, Wursthorn K, Chuang WL, Lau GK, Peng CY, et al. Telbivudine (LDT) plus peg-interferon (PEGIFN) in HBeAg-positive chronic hepatitis B—very potent antiviral efficacy but risk of peripheral neuropathy (PN). *J Hepatol*. 2010;52:S6–7.
29. Wursthorn K, Lutgehetmann M, Dandri M, Volz T, Buggisch P, Zollner B, et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. *Hepatology*. 2006;44:675–84.
30. Takkenberg B, Terpstra V, Zaaier H, Weegink C, Dijkgraaf M, Jansen P, et al. Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir. *J Gastroenterol Hepatol*. 2011;26:1527–35.
31. Hasan F, al-Khalidi J, Asker H, Varghese R, Siddique I, al-Shammali M, et al. Treatment of chronic hepatitis B with the sequential administration of interferon and lamivudine. *Hepato-gastroenterology*. 2003;50:2040–2.
32. Chan HL, Leung NW, Hui AY, Wong VW, Liew CT, Chim AM, et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. *Ann Intern Med*. 2005;142:240–50.
33. Chan HL, Hui AY, Wong VW, Chim AM, Wong ML, Sung JJ. Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B. *Hepatology*. 2005;41:1357–64.
34. Serfaty L, Thabut D, Zoulim F, Andreani T, Chazouillères O, Carbonell N, et al. Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: results of a pilot study. *Hepatology*. 2001;34:573–7.
35. Sarin SK, Sood A, Kumar M, Arora A, Amrapurkar D, Sharma BC, et al. Effect of lowering HBV DNA levels by initial antiviral therapy before adding immunomodulator on treatment of chronic hepatitis B. *Am J Gastroenterol*. 2007;102:96–104.
36. Manesis EK, Papatheodoridis GV, Hadziyannis SJ. A partially overlapping treatment course with lamivudine and interferon in hepatitis B e antigen-negative chronic hepatitis B. *Aliment Pharmacol Ther*. 2006;23:99–106.
37. Vassiliadis T, Tziomalos K, Patsiaoura K, Zagris T, Giouleme O, Soufleris K, et al. Lamivudine/pegylated interferon alpha-2b sequential combination therapy compared with lamivudine monotherapy in HBeAg-negative chronic hepatitis B. *J Gastroenterol Hepatol*. 2007;22:1582–8.
38. Shi M, Wang RS, Zhang H, Zhu YF, Han B, Zhang Y, et al. Sequential treatment with lamivudine and interferon-alpha monotherapies in hepatitis B e antigen-negative Chinese patients and its suppression of lamivudine-resistant mutations. *J Antimicrob Chemother*. 2006;58:1031–5.
39. Orito E, Ichida T, Sakugawa H, Sata M, Horiike N, Hino K, et al. Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan. *Hepatology*. 2001;34:590–4.
40. Enomoto M, Tamori A, Nishiguchi S. Hepatitis B virus genotypes and response to antiviral therapy. *Clin Lab*. 2006;52:43–7.
41. Enomoto M, Tamori A, Kohmoto MT, Hayashi T, Jomura H, Habu D, et al. Lamivudine and IFN-beta sequential therapy in HBe antigen-positive patients with chronic hepatitis B virus genotype C infection. *J Interferon Cytokine Res*. 2007;27:201–7.
42. Minami M, Okanoue T. Management of HBV infection in Japan. *Hepatol Res*. 2007;37[s1]:S79–82.
43. Okuse C, Yotsuyanagi H, Yamada N, Okamoto M, Ikeda H, Kobayashi M, et al. Effect of nucleoside analog-interferon sequential therapy on patients with acute exacerbation of chronic hepatitis B. *Hepatol Res*. 2010;40:461–9.
44. Moucari R, Boyer N, Ripault MP, Castelnau C, Mackiewicz V, Dauvergne A, et al. Sequential therapy with adefovir dipivoxil and pegylated interferon alpha-2a for HBeAg-negative patients. *J Viral Hepat*. 2011;18:580–6.
45. Enomoto M, Nishiguchi S, Tamori A, Kobayashi S, Sakaguchi H, Shiomi S, et al. Entecavir and interferon- α sequential therapy in Japanese patients with hepatitis B e antigen-positive chronic hepatitis B. *J Gastroenterol* 2012. doi: 10.1007/s00535-012-0645-5.
46. Chen CC, Wang PC, Chang HW, Chen CF. Safety and efficacy of two-step peginterferon α -2a treatment in patients of chronic hepatitis B with acute exacerbation. *J Viral Hepat*. 2012;19:161–72.
47. Matsumoto A, Tanaka E, Suzuki Y, Kobayashi M, Tanaka Y, Shinkai N, et al. Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B. *Hepatol Res*. 2012;42:139–49.
48. Kozuka R, Enomoto M, Morikawa H, Tamori A, Kawada N. Anti-hepatitis B virus therapy: to stop, or not to stop: has the question been solved? *Hepatol Res*. 2012;42:946–7.
49. Kumada H, Okanoue T, Onji M, Moriwaki H, Izumi N, Tanaka E, et al. Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis B virus infection for the fiscal year 2008 in Japan. *Hepatol Res*. 2010;40:1–7.
50. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. *Hepatology*. 2009;49:1503–14.
51. Snow-Lampart A, Chappell B, Curtis M, Zhu Y, Myrick F, Schwalder J, et al. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients mono-infected with chronic hepatitis B virus. *Hepatology*. 2011;53:763–73.
52. Kittner JM, Sprinzl MF, Grambihler A, Weinmann A, Schattnerberg JM, Galle PR, et al. Adding pegylated interferon to a current nucleos(t)ide therapy leads to HBsAg seroconversion in a subgroup of patients with chronic hepatitis B. *J Clin Virol*. 2012;54:93–5.

Significant background rates of HBV and HCV infections in patients and risks of blood transfusion from donors with low anti-HBc titres or high anti-HBc titres with high anti-HBs titres in Japan: a prospective, individual NAT study of transfusion-transmitted HBV, HCV and HIV infections

Y. Tani,¹ H. Aso,¹ H. Matsukura,¹ K. Tadokoro,² A. Tamori,³ S. Nishiguchi,⁴ H. Yoshizawa⁵, H. Shibata,¹ & JRC NAT Screening Research Group

¹Japanese Red Cross Osaka Blood Center, Osaka, Japan

²Japanese Red Cross Central Blood Institute, Tokyo, Japan

³Osaka City University Hospital, Osaka, Japan

⁴Hyogo College of Medicine, Hyogo, Japan

⁵Hiroshima University, Graduate School of Biomedical Sciences, Hiroshima, Japan

Vox Sanguinis

Background The Japanese Red Cross (JRC) conducted a prospective study to evaluate the frequency of transfusion-transmitted HBV, HCV and HIV infections to assess the risk of transfusion of blood components routinely supplied to hospitals.

Study Design and Methods Post-transfusion specimens from patients at eight medical institutes were examined for evidence of infection with HBV (2139 cases), HCV (2091) and HIV (2040) using individual nucleic acid amplification testing (NAT). If these specimens were reactive, pre-transfusion specimens were also examined for the virus concerned by individual NAT. In the event that the pre-transfusion specimen was non-reactive, then all repository specimens from implicated donors were tested for the viruses by individual donation NAT. In addition, a further study was carried out to evaluate the risk of transfusion of components from donors with low anti-HBc titres or high anti-HBc with high anti-HBs titres.

Results Transfusion-transmitted HCV and HIV infections were not observed. One case of post-transfusion HBV infection was identified (rate, 0.0004675; 95% CI for the risk of transmission, 1 in 451–41 841). The background rates of HBV, HCV and HIV infections in patients prior to transfusion were 3.4% (72/2139), 7.2% (150/2091) and 0% (0/2040), respectively. Sixty-four anti-HBc- and/or anti-HBs-reactive blood components were transfused to 52 patients non-reactive for anti-HBc or anti-HBs before and after transfusion (rate, 0; 95% CI for the risk of transmission, <1 in 22).

Conclusion This study demonstrated that the current criteria employed by JRC have a low risk, but the background rates of HBV and HCV infections in Japanese patients are significant.

Key words: nucleic acid amplification testing, occult HBV infection, transfusion-transmitted viral infection.

Received: 25 January 2011,
revised 4 July 2011,
accepted 15 July 2011,
published online 14 November 2011

Correspondence: Yoshihiko Tani, MD, PhD, Japanese Red Cross Osaka Blood Center, 2-4-43 Morinomiya, Joto-Ku, Osaka 536-8505, Japan
E-mail: tani@osaka.bc.jrc.or.jp

Introduction

In Japan, all blood components are collected from non-remunerated voluntary donors by the Japanese Red Cross (JRC). Subsequently, the components are screened by serological testing for syphilis, HBV, HCV, HIV, HTLV-1 and human parvovirus B19, and serologically non-reactive components (the criteria to determine the suitability of blood for supply, which are based on infectious markers, are shown in Table 1) are then subjected to nucleic acid amplification testing (NAT) for HBV DNA, HCV RNA, and HIV-1 RNA in a mini-pool (MP) using an automated multiplex assay system (AMPLINAT MPX; Roche Diagnostics) that can amplify these three viruses simultaneously [1]. When all the above-mentioned tests are non-reactive, the blood components are supplied to hospitals. An important point is that unlike some other countries [2], blood components from donors non-reactive for HBsAg and HBV DNA but reactive for anti-HBc titres of <1:32 or anti-HBc titres of $\geq 1:32$ with anti-HBs ≥ 200 mIU/ml are considered suitable for transfusion in Japan on the basis of a study of the correlation between anti-HBc titres and HBV DNA levels in blood units without detectable HBsAg [3, 4].

Since the introduction of the automated NAT multiplex assay system by the JRC in October 1999, the risk of transmission of HBV, HIV and HCV via transfusion has reduced significantly in Japan [5, 6]. However, several cases of transfusion-transmitted viral infections, especially of HBV, continue to occur each year [7]. This is partly because the

doubling time of HBV is longer than that of HCV or HIV [8, 9], and thus, the NAT window period is also longer. The other reason is that occult HBV-infected donors [3] with low anti-HBc titres and low levels of HBV DNA that are not detected by MP-NAT may not be identified [10].

In this study, we randomly selected five JRC blood centres (Hokkaido, Iwate, Osaka, Ehime, and Fukuoka) and eight hospitals within the jurisdiction of these centres and prospectively investigated the risk involved in routine blood transfusion to patients in these hospitals. In addition, we also examined the safety of blood transfusion from anti-HBc-positive donors with anti-HBc titres of <1:32 or anti-HBc titres of $\geq 1:32$ with anti-HBs ≥ 200 mIU/ml.

Materials and methods

Serological tests on donated blood

All donated blood samples were serologically screened as shown in Table 1.

NAT

The NAT screening system used in Japan has been reported previously by Mine *et al.* [12]. In brief, NAT screening is performed using a multiplex system capable of simultaneous detection of HBV DNA, HCV RNA and HIV-1 RNA to reduce the cost and ensure that the test is completed within 72 h. Samples are tested in MPs of 50 with the ability to detect 185–550 IU/ml for HBV, 3050–5600 IU/ml for HCV

Table 1 Criteria for infectious and other markers

Pathogens	Serological tests		
	Contents	Methods	Criteria
Syphilis	Serodiagnosis	<i>Treponema pallidum</i> particle agglutination (TPPA) ^a	Non-reactive
HIV	Anti-HIV-1/2	Agglutination of gelatin particles coated with recombinant HIV-1/2 proteins ^a	Non-reactive
HCV	Anti-HCV	Passive hemagglutination (PHA ^b) or particle agglutination (PA ^a)	Non-reactive
HBV	HBsAg	Reverse passive hemagglutination (RPHA ^c)	Non-reactive
	Anti-HBs	PHA ^c	– ^d
	Anti-HBc	Haemagglutination inhibition (HI ^e)	
HTLV-1	Anti-HTLV-1	PA ^a	Non-reactive
B19	Anti-B19	Receptor-mediated hemagglutination (RHA ^e)	
Others	Serum ALT	Method of Wroblewski and LaDue (11)	≤ 60 IU/ml

^aFujirebio Inc., Tokyo, Japan.

^bDainabot Co. Ltd., Tokyo, Japan.

^cReagents prepared by JRC.

^dBlood units with the following profile were excluded from being transfused: 1. Specimen reactive for HBsAg on RPHA, with the result subsequently confirmed by enzyme immune assay (EIA). 2. Specimen reactive for anti-HBc at a dilution of 1:32 or higher on HI and in which anti-HBs is either absent or at a level of not more than 200 mIU/ml.

^eRHA using reagents prepared by JRC.

and 1650–3300 IU/ml for HIV in donations contained within the pool.

In this study, HBV DNA, HCV RNA and HIV-1 RNA from patients were individually tested using the modified methods of Iizuka *et al.* [4], Okamoto *et al.* [13] and Matsumoto *et al.* [14], respectively, at the JRC NAT centres in Hokkaido and Kyoto. The analytical sensitivity cut-off of ID-NAT was 3.7–11 IU/ml for HBV, 61–112 IU/ml for HCV and 33–66 IU/ml for HIV [1].

Criteria for blood transfusion

The serological test criteria for the release of blood donations in Japan are shown in Table 1. Donations must also be non-reactive for HBV DNA, HCV RNA and HIV RNA on 50-MP-NAT.

Study design

Informed consent was obtained from each patient before transfusion between November 2003 and December 2006 at eight hospitals [Asahikawa Medical College Hospital (Hokkaido); Iwate Medical University Hospital (Iwate); Osaka City University Hospital, Osaka City General Hospital, Osaka Red Cross Hospital (Osaka); National Hospital Organization Shikoku Cancer Center, Ehime Red Cross Hospital (Ehime); and Fukuoka University Hospital (Fukuoka)]. In total, 2139 patients who survived 3 months after

transfusion (approximately 40% of patients died of their original disease or complications within 3 months) were enrolled in this study. Their pre-transfusion blood specimens had been collected and cryopreserved in these hospitals (Fig. 1).

Approximately 3 months after blood transfusion, post-transfusion specimens were collected from the patients and individually tested for HBV DNA, HCV RNA and HIV-1 RNA at the JRC NAT centres. In the case of neonates and elderly patients, when the specimen volume was insufficient to perform NAT for all the three viruses, the priority of examination was HBV DNA >HCV RNA >HIV-1 RNA.

If the post-transfusion specimen was non-reactive for all the three viruses, the study was terminated for the patient concerned. However, if the specimen was reactive, the patient's cryopreserved pre-transfusion specimen was tested for the virus concerned by NAT. If the pre-transfusion specimen was reactive, it was concluded that the patient was infected before transfusion. However, if the pre-transfusion specimen was non-reactive, all repository specimens from the implicated donors, which were drawn at the time of blood donation and cryopreserved at the JRC NAT centres, were also tested for the virus concerned by ID-NAT, as reported by Satake *et al.* [15]. If these specimens were non-reactive and the case was restricted to HBV, the remaining pre-transfusion specimen of the patient was serologically tested for anti-HBc, anti-HBs and/or HBsAg using an enzyme immunoassay




Fig. 1 Study design. Step 1: After obtaining informed consent from patients, pre-transfusion specimens were collected and cryopreserved. Step 2: Approximately 3 months after blood transfusion, post-transfusion specimens were collected from the patients at the eight hospitals and individually tested for HBV DNA, HCV RNA and HIV-1 RNA at the JRC nucleic acid amplification testing (NAT) centres. Step 3: If the post-transfusion specimen was reactive, the patient's pre-transfusion specimen was tested for the virus concerned by NAT. Step 4: If the pre-transfusion specimen was non-reactive (this was restricted to HBV alone), all repository specimens from the donors concerned were also tested for HBV DNA by ID-NAT. If these specimens were non-reactive, the remaining pre-transfusion specimen of the patient was then serologically tested for anti-HBc, anti-HBs and/or HBsAg.